ICMR disbands committee formed on research for drug and vaccine

MUMBAI: The Indian Council of Medical Research (ICMR) has disbanded a committee tasked with research for developing a vaccine and drugs to deal with the Covid-19 pandemic, a member of the panel said. No reason was given for the decision by country’s top health body.

The panel was constituted on April 6 and had looked at 100 vaccine candidates and was in the process of identifying new areas of drug and vaccine development.
Debashis Mitra of the National Centre for Cell Science, who was one of the nine members on the committee said, “We got a mail from the chairman (of ICMR) in this regard a few days ago. The panel had met three times in a span of 10 days. However, after the third meeting, the committee was dissolved; we were told that the Department of Biotechnology (DBT) will now look into this.”

The ICMR had formed a task force with five groups on April 6, . These were in the areas of clinical research, research on diagnostics and bio-markers, epidemiology and surveillance, operations research and vaccines/drug research and development. In February, the DBT had formed a group to look at drugs and vaccines research for Covid-19 and had called for proposals from companies.

  • Related Posts

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

    BMJ Research Forum all set to mull over in Delhi on September 5 New Delhi: Research in healthcare in India is a dime a dozen. But the real question that…

    Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

    Dr Rajendra Pratap Gupta gets nominated to advise UN Secretary General Geneva/ New Delhi: Former advisor to Union Health Minister of India JP Nadda in his earlier stint and a…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Puresta launches EVERQ, AI-powered skin-health platform

    Puresta launches EVERQ, AI-powered skin-health platform

    Stem cell therapy for autism only in approved clinical trials: Centre

    Stem cell therapy for autism only in approved clinical trials: Centre